Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

4 treatments under study, led by Control

Related Conditions

Often studied with 16 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

2Total
Phase 2 (1)
Phase 4 (1)

Trial Status

Completed3

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 3 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT00001154CompletedPrimary

Lipoprotein Metabolism in Normal Volunteers and Patients With High Levels of Lipoproteins

NCT00362180Phase 2Completed

Measure Liver Fat Content After ISIS 301012 (Mipomersen) Administration

NCT00298909Phase 4Completed

Exercise Versus Niacin in Patients With Coronary Artery Disease (CAD) and Low High-Density Lipoproteins (HDL)

Showing all 3 trials

Research Network

Common Treatments

  • Control1
  • Niacin1
  • Physical Exercise1
  • Mipomersen1

Active Sponsors

  • National Heart, Lung, and Blood Institute (NHLBI)1
  • University of Leipzig1
  • Kastle Therapeutics, LLC1
  • Ionis Pharmaceuticals, Inc.1

Top Investigators

Related Conditions

  • Hypercholesterolemia2
  • Congenital Abnormalities1
  • Hyperlipidemias1
  • Dyslipidemia1
  • Dyslipidemias1

Activity Timeline